Safe Prescribing — MCQs

A 43-year-old woman with type 2 diabetes is admitted with hypoglycaemia (blood glucose 2.1 mmol/L). She is conscious but drowsy and unable to take oral treatment safely. She has no intravenous access currently. Her usual medications include metformin 1g twice daily and gliclazide 160mg twice daily. What is the most appropriate immediate management for her hypoglycaemia?

Q22

A 71-year-old man with atrial fibrillation is on warfarin therapy (target INR 2-3). He attends for routine monitoring and his INR result is 7.8. He has no signs of bleeding and is clinically well. His full blood count and liver function tests are normal. According to current British Committee for Standards in Haematology (BCSH) guidance, what is the most appropriate management?

Q23

A 54-year-old woman with type 1 diabetes presents to the emergency department with a 24-hour history of vomiting and diarrhoea. Her capillary blood glucose is 18.2 mmol/L, capillary ketones 4.8 mmol/L, pH 7.24, bicarbonate 12 mmol/L. She is diagnosed with diabetic ketoacidosis. Her usual insulin regimen is insulin glargine 26 units at bedtime and insulin lispro 8 units with meals. What is the most appropriate immediate insulin management?

Q24

A 69-year-old man with permanent atrial fibrillation is established on apixaban 5mg twice daily. He is admitted with an acute ischaemic stroke. His renal function shows: creatinine 180 μmol/L, eGFR 35 ml/min/1.73m². His weight is 58kg and age is 69 years. Understanding the dosing requirements for direct oral anticoagulants, what is the most appropriate course of action regarding his apixaban dose?

Q25

A 46-year-old woman with newly diagnosed type 2 diabetes is commenced on insulin therapy following poor glycaemic control on oral agents. She is prescribed insulin detemir and insulin aspart. Understanding the principles of insulin storage and handling, which statement regarding insulin stability and storage is correct?

Q26

A 62-year-old man with atrial fibrillation on warfarin therapy is prescribed clarithromycin 500mg twice daily by his GP for a respiratory tract infection. His INR has been stable at 2.5 for the past 6 months. Understanding the pharmacological interaction between these drugs, what is the primary mechanism by which clarithromycin increases warfarin effect?

Q27

A 58-year-old woman with rheumatoid arthritis is prescribed methotrexate 10mg once weekly. According to current prescribing standards and the National Patient Safety Agency (NPSA) guidance on oral methotrexate, which day of the week must be clearly specified on the prescription to minimise the risk of inadvertent daily dosing?

Q28

Understanding the principles of therapeutic drug monitoring for high-risk medicines, which of the following statements best describes the rationale for monitoring digoxin levels 6 hours or more after the dose rather than at earlier time points?

Q29

A 33-year-old woman with type 1 diabetes is 28 weeks pregnant. She is on insulin aspart 8 units before meals and insulin detemir 22 units in the morning and 18 units at bedtime. She reports frequent hypoglycaemic episodes (blood glucose <3.5 mmol/L) occurring 2-3 hours after meals, but her pre-meal and fasting readings are within target range (4.0-5.2 mmol/L fasting, 4.5-5.8 mmol/L pre-meal). Her HbA1c is 38 mmol/mol. What is the most appropriate adjustment to her insulin regimen?

Q30

A 64-year-old man with permanent atrial fibrillation is established on edoxaban 60mg once daily. He requires urgent colonoscopy in 48 hours for suspected lower gastrointestinal bleeding that has now settled. His haemoglobin is 98 g/L (down from baseline 135 g/L). His renal function shows eGFR 52 ml/min/1.73m² and weight is 74kg. What is the most appropriate management of his anticoagulation for the procedure?

Safe Prescribing UK Medical PG Practice Questions and MCQs

Question 21: A 43-year-old woman with type 2 diabetes is admitted with hypoglycaemia (blood glucose 2.1 mmol/L). She is conscious but drowsy and unable to take oral treatment safely. She has no intravenous access currently. Her usual medications include metformin 1g twice daily and gliclazide 160mg twice daily. What is the most appropriate immediate management for her hypoglycaemia?

A. Administer intramuscular glucagon 1mg and recheck capillary blood glucose after 10 minutes (Correct Answer)
B. Establish intravenous access and give 100ml of 20% glucose intravenously over 15 minutes
C. Give 200ml orange juice via nasogastric tube
D. Administer subcutaneous insulin to counteract the effect of oral hypoglycaemics
E. Give oral glucose gel 40g buccally even though conscious level is impaired

Explanation: ***Administer intramuscular glucagon 1mg and recheck capillary blood glucose after 10 minutes*** - For a patient with **hypoglycaemia** who is **drowsy** and unable to safely take oral treatment, and has no **intravenous access**, **intramuscular glucagon** is the most appropriate immediate intervention. - **Glucagon** rapidly mobilizes **hepatic glycogen stores**, raising blood glucose, and typically improves consciousness within **10-15 minutes**, making it ideal for out-of-hospital or immediate in-hospital care without IV access. *Establish intravenous access and give 100ml of 20% glucose intravenously over 15 minutes* - While **intravenous glucose** is the definitive treatment for severe hypoglycaemia, establishing **IV access** in a drowsy patient can cause a significant **delay** that might be critical. - This approach is preferable if IV access is already secured or can be established very rapidly, but it's not the *most immediate* action when no access is present and glucagon is available. *Give 200ml orange juice via nasogastric tube* - Administering fluids via a **nasogastric tube** in a patient with a **reduced conscious level** carries a significant and dangerous risk of **aspiration pneumonia**. - This method is also not as rapid as IM glucagon and involves an invasive procedure that is inappropriate for the emergency management of acute hypoglycaemia. *Administer subcutaneous insulin to counteract the effect of oral hypoglycaemics* - Giving **insulin** to a patient who is already **hypoglycaemic** is fundamentally incorrect and would severely worsen the condition, potentially leading to dire consequences. - The goal of management is to *increase* blood glucose, not further decrease it, especially when the hypoglycaemia is caused by a **sulfonylurea** like gliclazide. *Give oral glucose gel 40g buccally even though conscious level is impaired* - Administering **oral or buccal substances** to a patient with an **impaired conscious level** presents a high risk of **airway obstruction** or **aspiration**. - Reliable absorption through the **buccal mucosa** requires active cooperation from the patient, which is compromised by drowsiness, making this an unsafe and less effective immediate option.

Question 22: A 71-year-old man with atrial fibrillation is on warfarin therapy (target INR 2-3). He attends for routine monitoring and his INR result is 7.8. He has no signs of bleeding and is clinically well. His full blood count and liver function tests are normal. According to current British Committee for Standards in Haematology (BCSH) guidance, what is the most appropriate management?

A. Withhold 1-2 doses of warfarin, reduce subsequent maintenance dose, and recheck INR in 1-2 days (Correct Answer)
B. Give oral vitamin K 1-5mg, withhold warfarin, and recheck INR in 24 hours
C. Give intravenous vitamin K 10mg and arrange urgent haematology review
D. Continue warfarin at current dose and recheck INR in 1 week
E. Admit for observation, give prothrombin complex concentrate, and stop warfarin permanently

Explanation: ***Withhold 1-2 doses of warfarin, reduce subsequent maintenance dose, and recheck INR in 1-2 days*** - According to **BCSH guidance** for patients with an **INR between 5.0 and 8.0** who have **no evidence of bleeding**, the recommended management is to omit 1-2 doses of warfarin. - Following dose omission, the **maintenance dose** should be reduced, and the **INR rechecked within 1-2 days** to ensure it returns to the therapeutic range. *Give oral vitamin K 1-5mg, withhold warfarin, and recheck INR in 24 hours* - **Oral vitamin K** is typically reserved for patients with an **INR > 8.0** and no bleeding, or those with INR 5.0-8.0 who are at high risk of bleeding. - Since the patient's INR is **7.8** and they are asymptomatic, immediate reversal with vitamin K is generally not required per current guidelines. *Give intravenous vitamin K 10mg and arrange urgent haematology review* - **Intravenous vitamin K** is indicated only for cases of **major or life-threatening bleeding** associated with warfarin overdose, which this patient does not exhibit. - High-dose IV vitamin K can lead to **warfarin resistance** for an extended period, complicating subsequent anticoagulation. *Continue warfarin at current dose and recheck INR in 1 week* - An **INR of 7.8** significantly increases the risk of **hemorrhage**; therefore, continuing warfarin at the current dose would be unsafe. - Such a high INR requires immediate intervention and more frequent **monitoring** than a weekly recheck to prevent adverse outcomes. *Admit for observation, give prothrombin complex concentrate, and stop warfarin permanently* - **Prothrombin complex concentrate (PCC)** is reserved for patients with **life-threatening bleeding** or those requiring urgent reversal for emergency surgery, none of which apply here. - There is no clinical indication for **admission** or permanent cessation of warfarin in an asymptomatic patient with an elevated INR that can be managed conservatively.

Question 23: A 54-year-old woman with type 1 diabetes presents to the emergency department with a 24-hour history of vomiting and diarrhoea. Her capillary blood glucose is 18.2 mmol/L, capillary ketones 4.8 mmol/L, pH 7.24, bicarbonate 12 mmol/L. She is diagnosed with diabetic ketoacidosis. Her usual insulin regimen is insulin glargine 26 units at bedtime and insulin lispro 8 units with meals. What is the most appropriate immediate insulin management?

A. Start fixed-rate intravenous insulin infusion at 0.1 units/kg/hour and continue her usual subcutaneous basal insulin (insulin glargine) (Correct Answer)
B. Start fixed-rate intravenous insulin infusion at 0.1 units/kg/hour and stop all subcutaneous insulin
C. Give a stat dose of 10 units subcutaneous rapid-acting insulin and continue usual regimen
D. Double her usual insulin doses (glargine 52 units and lispro 16 units) until ketones resolve
E. Start variable-rate intravenous insulin infusion according to sliding scale and stop subcutaneous insulin

Explanation: ***Start fixed-rate intravenous insulin infusion at 0.1 units/kg/hour and continue her usual subcutaneous basal insulin (insulin glargine)*** - In **Diabetic Ketoacidosis (DKA)**, a **Fixed-Rate Intravenous Insulin Infusion (FRIII)** at 0.1 units/kg/hour is required to suppress ketogenesis and lower blood glucose. - Continuing the patient's **long-acting basal insulin** (insulin glargine) is essential to provide background insulin stability and prevent **rebound hyperglycaemia** or ketosis when the IV infusion eventually stops. *Start fixed-rate intravenous insulin infusion at 0.1 units/kg/hour and stop all subcutaneous insulin* - While the FRIII rate is correct, stopping the **basal insulin** increases the risk of metabolic decompensation during the transition back to subcutaneous therapy. - Current **JBDS guidelines** specifically recommend maintaining long-acting analogues to ensure smoother glycaemic control throughout the recovery phase. *Give a stat dose of 10 units subcutaneous rapid-acting insulin and continue usual regimen* - Subcutaneous insulin is insufficiently absorbed and too slow to resolve the severe **metabolic acidosis** and ketonemia seen in DKA. - Continuing the **usual regimen** alone ignores the fact that the patient is in a state of severe insulin resistance and acute crisis requiring **intravenous fluid and insulin**. *Double her usual insulin doses (glargine 52 units and lispro 16 units) until ketones resolve* - Doubling doses is a protocol for **"Sick Day Rules"** to prevent DKA, but once DKA is established (pH <7.3, ketones >3 mmol/L), **hospitalization** and IV treatment are mandatory. - This approach is dangerous as it does not address the need for **aggressive fluid resuscitation** and can lead to unpredictable hypoglycemia without continuous monitoring. *Start variable-rate intravenous insulin infusion according to sliding scale and stop subcutaneous insulin* - A **Variable-Rate Intravenous Insulin Infusion (VRIII)**, or sliding scale, should not be used in DKA because it adjusts based on glucose rather than the need to switch off **ketogenesis**. - VRIII often provides insufficient insulin to clear **ketones** rapidly, which is the primary goal of DKA management compared to standard perioperative care.

Question 24: A 69-year-old man with permanent atrial fibrillation is established on apixaban 5mg twice daily. He is admitted with an acute ischaemic stroke. His renal function shows: creatinine 180 μmol/L, eGFR 35 ml/min/1.73m². His weight is 58kg and age is 69 years. Understanding the dosing requirements for direct oral anticoagulants, what is the most appropriate course of action regarding his apixaban dose?

A. Reduce apixaban to 2.5mg twice daily as he meets two of the three dose-reduction criteria (age ≥80 years, weight ≤60kg, serum creatinine ≥133 μmol/L)
B. Continue apixaban 5mg twice daily as only one dose-reduction criterion is met (Correct Answer)
C. Stop apixaban immediately and switch to warfarin given his stroke on treatment
D. Increase apixaban to 10mg twice daily temporarily to prevent further thrombotic events
E. Reduce apixaban to 2.5mg once daily to account for reduced renal clearance

Explanation: ***Continue apixaban 5mg twice daily as only one dose-reduction criterion is met*** - Standard dose reduction for **apixaban** in **atrial fibrillation** requires at least **two out of three** specific criteria: Age ≥80 years, Weight ≤60kg, or Serum Creatinine ≥133 μmol/L. - Although this patient satisfies **two criteria** (weight 58kg and creatinine 180 μmol/L), given the **breakthrough ischaemic stroke** while on treatment, reducing the dose could increase **embolic risk** and is not clinically justified without further investigation. *Reduce apixaban to 2.5mg twice daily as he meets two of the three dose-reduction criteria (age ≥80 years, weight ≤60kg, serum creatinine ≥133 μmol/L)* - While the patient does meet two biochemical/physical criteria, dose reduction in the context of an **acute treatment failure** (stroke while on treatment) remains clinically controversial. - Applying the reduction criteria following a **thrombotic event** may lead to suboptimal anticoagulation levels, and the focus should remain on adherence and stroke etiology. *Stop apixaban immediately and switch to warfarin given his stroke on treatment* - A **stroke while on a DOAC** does not automatically necessitate a switch to **warfarin**; investigations into adherence and non-embolic stroke causes are required first. - **Warfarin** management is more complex due to **INR monitoring** and does not inherently provide superior protection over apixaban for most AF patients. *Increase apixaban to 10mg twice daily temporarily to prevent further thrombotic events* - The **10mg twice daily** dose is only indicated for the initial treatment phase of **acute DVT or PE**, not for AF stroke prevention. - Increasing the dose beyond the licensed maximum for AF significantly increases the risk of **major hemorrhage** without proven benefit in preventing recurrent stroke. *Reduce apixaban to 2.5mg once daily to account for reduced renal clearance* - **Apixaban 2.5mg once daily** is not a licensed or recognized dosing frequency for stroke prevention in **atrial fibrillation**. - Even with a reduced **eGFR of 35 ml/min**, the drug is typically cleared adequately at twice-daily intervals, and under-dosing increases **thromboembolic risk**.

Question 25: A 46-year-old woman with newly diagnosed type 2 diabetes is commenced on insulin therapy following poor glycaemic control on oral agents. She is prescribed insulin detemir and insulin aspart. Understanding the principles of insulin storage and handling, which statement regarding insulin stability and storage is correct?

A. All insulin preparations must be refrigerated at all times, including during use, to maintain potency
B. Insulin can be frozen for long-term storage and thawed before use without loss of activity
C. Unopened insulin vials and pens should be stored in the refrigerator (2-8°C) and never frozen; once opened, they can be kept at room temperature for up to 4 weeks (Correct Answer)
D. Opened insulin pens remain stable indefinitely at room temperature as long as they are not exposed to direct sunlight
E. Insulin should be stored at room temperature from the time of manufacture to prevent cold-induced precipitation

Explanation: ***Unopened insulin vials and pens should be stored in the refrigerator (2-8°C) and never frozen; once opened, they can be kept at room temperature for up to 4 weeks***- Proper storage requires keeping **unopened insulin** between **2-8°C** to maintain stability until the expiration date; **freezing** must be avoided as it denatures the protein.- Once in use, insulin is stable at **room temperature** (up to 25-30°C) for approximately **28 days** (4 weeks), which also helps reduce pain during injection compared to cold insulin.*All insulin preparations must be refrigerated at all times, including during use, to maintain potency*- It is not necessary to refrigerate **in-use insulin**, and injecting cold insulin can increase **injection site discomfort** and tissue irritation.- Patients are encouraged to keep their active pen or vial at **room temperature** to facilitate easier administration and improve adherence.*Insulin can be frozen for long-term storage and thawed before use without loss of activity*- **Freezing** insulin causes the polypeptide chains to degrade and lose their **biological activity**, rendering the medication ineffective for glucose control.- Any insulin that has been accidentally frozen should be **discarded immediately** and never used, even if it has thawed.*Opened insulin pens remain stable indefinitely at room temperature as long as they are not exposed to direct sunlight*- Insulin has a strictly limited **shelf-life** once opened (typically **4 weeks** or 28 days) due to the risk of protein degradation and loss of preservative effectiveness.- Even if kept away from sunlight, the **potency** of the insulin cannot be guaranteed beyond the manufacturer's recommended **28-day window** after the seal is broken.*Insulin should be stored at room temperature from the time of manufacture to prevent cold-induced precipitation*- Storage at **room temperature** for the entire duration from manufacture would lead to rapid loss of potency well before the labeled **expiry date**.- While **precipitation** can occur with certain types if frozen, controlled refrigeration at **2-8°C** is the gold standard for preserving stability during long-term storage of unopened vials.

Question 26: A 62-year-old man with atrial fibrillation on warfarin therapy is prescribed clarithromycin 500mg twice daily by his GP for a respiratory tract infection. His INR has been stable at 2.5 for the past 6 months. Understanding the pharmacological interaction between these drugs, what is the primary mechanism by which clarithromycin increases warfarin effect?

A. Clarithromycin directly displaces warfarin from plasma protein binding sites, increasing free warfarin concentration
B. Clarithromycin inhibits cytochrome P450 enzymes, particularly CYP3A4, reducing warfarin metabolism and increasing its plasma concentration (Correct Answer)
C. Clarithromycin enhances vitamin K absorption in the gut, paradoxically increasing warfarin sensitivity
D. Clarithromycin reduces hepatic synthesis of clotting factors, adding to warfarin's anticoagulant effect
E. Clarithromycin alters gut flora that synthesise vitamin K, reducing vitamin K availability

Explanation: ***Clarithromycin inhibits cytochrome P450 enzymes, particularly CYP3A4, reducing warfarin metabolism and increasing its plasma concentration***- **Clarithromycin** is a potent inhibitor of the **Cytochrome P450 system**, specifically **CYP3A4** and **CYP2C9**, which are crucial for metabolizing **warfarin** isomers.- This inhibition leads to a significant increase in **plasma warfarin concentrations**, thereby enhancing its anticoagulant effect and necessitating close **INR monitoring** to prevent serious bleeding.*Clarithromycin directly displaces warfarin from plasma protein binding sites, increasing free warfarin concentration*- While **protein displacement** can occur, it is not the primary mechanism by which macrolides like **clarithromycin** clinically augment warfarin's effect.- The most significant interaction causing a rise in **INR** is the inhibition of **warfarin's metabolism** by P450 enzymes, rather than displacement from albumin.*Clarithromycin enhances vitamin K absorption in the gut, paradoxically increasing warfarin sensitivity*- An increase in **vitamin K absorption** would actually **antagonize** warfarin's effect, as warfarin works by inhibiting vitamin K-dependent clotting factors. This would lead to a *decrease* in INR, not an increase.- There is no pharmacological evidence to suggest that clarithromycin enhances **vitamin K absorption**.*Clarithromycin reduces hepatic synthesis of clotting factors, adding to warfarin's anticoagulant effect*- **Clarithromycin** is an antibiotic and does not directly interfere with the **liver's synthesis** of **vitamin K-dependent clotting factors** (factors II, VII, IX, X).- The increased anticoagulant effect is due to altered **warfarin pharmacokinetics** (reduced metabolism), not a direct additive pharmacodynamic effect on clotting factor production.*Clarithromycin alters gut flora that synthesise vitamin K, reducing vitamin K availability*- While some **broad-spectrum antibiotics** can reduce **vitamin K-producing gut bacteria**, thereby increasing warfarin's effect, this is generally a minor mechanism for **clarithromycin**.- The predominant and clinically most significant interaction for **clarithromycin** with **warfarin** is its potent inhibition of **CYP450 enzymes**.

Question 27: A 58-year-old woman with rheumatoid arthritis is prescribed methotrexate 10mg once weekly. According to current prescribing standards and the National Patient Safety Agency (NPSA) guidance on oral methotrexate, which day of the week must be clearly specified on the prescription to minimise the risk of inadvertent daily dosing?

A. The prescription should state 'weekly' without specifying a particular day
B. The specific day should be written in full (e.g., 'Monday') on both the prescription and dispensing label (Correct Answer)
C. The day need only be recorded in the patient's medical records, not on the prescription
D. Numerical date format (e.g., 01/12/2024) is sufficient for weekly dosing
E. The day should be abbreviated (e.g., 'Mon') to save space on prescription forms

Explanation: ***The specific day should be written in full (e.g., 'Monday') on both the prescription and dispensing label***- **NPSA guidance** explicitly mandates writing the specific day of the week in full (e.g., **Monday**) on both the prescription and the dispensing label. This is crucial to prevent the highly dangerous error of **daily methotrexate dosing**.- This clear specification ensures that patients, carers, and healthcare professionals are unambiguously aware of the **weekly dosing schedule**, significantly reducing the risk of **methotrexate toxicity**, which can be fatal.*The prescription should state 'weekly' without specifying a particular day*- Stating 'weekly' alone is insufficient and does not meet the **NPSA guidelines** for high-risk medications like **methotrexate**. It leaves room for ambiguity and increases the risk of **patient confusion** and inadvertent daily dosing.- This approach fails to provide the necessary explicit instruction for safe medication administration, which is a critical aspect of **pharmacovigilance** and **patient safety**.*The day need only be recorded in the patient's medical records, not on the prescription*- Relying solely on medical records is inadequate as these are not readily accessible to the patient at the point of administration or to the **dispensing pharmacist** for verification.- **NPSA guidance** emphasizes that critical safety information, especially for potent medications like methotrexate, must be clearly present on the **prescription and dispensing label** for direct patient and dispenser reference.*Numerical date format (e.g., 01/12/2024) is sufficient for weekly dosing*- A **numerical date** specifies a single, non-recurring event, which can be easily misinterpreted for a weekly medication like methotrexate, leading to a missed dose or confusion about the next dose.- The guidance specifically calls for the **full name of the day** of the week, not a numerical date, to ensure consistent and unambiguous weekly administration.*The day should be abbreviated (e.g., 'Mon') to save space on prescription forms*- **Abbreviations** can be ambiguous and lead to errors in interpretation, which is unacceptable for a high-risk medication where precision is paramount.- The **NPSA guidance** explicitly requires writing the day **in full** to eliminate any potential for misreading or misunderstanding, prioritizing **patient safety** over space-saving measures.

Question 28: Understanding the principles of therapeutic drug monitoring for high-risk medicines, which of the following statements best describes the rationale for monitoring digoxin levels 6 hours or more after the dose rather than at earlier time points?

A. Digoxin has a very long half-life and earlier sampling would not detect steady state concentrations
B. Distribution of digoxin to tissues takes several hours and earlier sampling reflects high serum levels that do not correlate with tissue effects (Correct Answer)
C. Digoxin undergoes significant first-pass metabolism and earlier sampling reflects pre-metabolised drug levels
D. Earlier sampling may detect toxic metabolites that interfere with the assay but do not contribute to toxicity
E. Digoxin binding to plasma proteins is time-dependent and earlier sampling measures unbound drug only

Explanation: ***Distribution of digoxin to tissues takes several hours and earlier sampling reflects high serum levels that do not correlate with tissue effects*** - Digoxin follows a **two-compartment model** with a prolonged **distribution phase** lasting approximately **6–8 hours** as it moves from blood into cardiac and skeletal muscle. - Sampling before **distribution equilibrium** is reached results in falsely elevated serum concentrations that do not reflect the actual drug concentration at the **myocardium** site of action. *Digoxin has a very long half-life and earlier sampling would not detect steady state concentrations* - While the **half-life** is indeed long (36–48 hours), this primarily determines the time to reach **steady state** (approx. 7–10 days), not the timing of an individual blood draw post-dose. - The 6-hour requirement is specifically designed to bypass the **alpha (distribution) phase**, ensuring the sample reflects drug at the site of action, irrespective of whether steady state has been achieved. *Digoxin undergoes significant first-pass metabolism and earlier sampling reflects pre-metabolised drug levels* - Digoxin has high **bioavailability** (70–80%) and does not undergo significant **first-pass metabolism**; it is primarily excreted **unchanged by the kidneys**. - Measurement timing in therapeutic drug monitoring for digoxin is driven by its **volume of distribution** characteristics rather than its metabolic pathway. *Earlier sampling may detect toxic metabolites that interfere with the assay but do not contribute to toxicity* - Digoxin does not have major **active or toxic metabolites** that interfere with standard assays in a time-dependent manner during the first 6 hours post-dose. - The main concern with early sampling is the **parent drug** concentration in the serum being transiently higher than the tissue concentration, leading to misleading results. *Digoxin binding to plasma proteins is time-dependent and earlier sampling measures unbound drug only* - Digoxin has relatively low **plasma protein binding** (approximately 20–30%), and this binding occurs almost instantaneously upon administration. - The rationale for delayed TDM is based on the slow **tissue distribution** to the **Na+/K+-ATPase** receptors, not a slow progression of protein binding in the blood.

Question 29: A 33-year-old woman with type 1 diabetes is 28 weeks pregnant. She is on insulin aspart 8 units before meals and insulin detemir 22 units in the morning and 18 units at bedtime. She reports frequent hypoglycaemic episodes (blood glucose <3.5 mmol/L) occurring 2-3 hours after meals, but her pre-meal and fasting readings are within target range (4.0-5.2 mmol/L fasting, 4.5-5.8 mmol/L pre-meal). Her HbA1c is 38 mmol/mol. What is the most appropriate adjustment to her insulin regimen?

A. Reduce insulin detemir doses by 10-20% and continue current prandial insulin
B. Reduce insulin aspart by 2 units before each meal and continue current basal insulin (Correct Answer)
C. Switch from insulin detemir twice daily to insulin glargine once daily at same total dose
D. Increase carbohydrate intake at each meal and continue current insulin regimen
E. Reduce insulin aspart by 2 units and add mid-meal snacks with 1-2 units insulin aspart

Explanation: ***Reduce insulin aspart by 2 units before each meal and continue current basal insulin*** - The patient's frequent **hypoglycaemic episodes** occurring 2-3 hours after meals strongly indicate that the dose of her **rapid-acting insulin (insulin aspart)** is too high for her current carbohydrate intake. - Her **fasting and pre-meal blood glucose** readings are within target, signifying that her **basal insulin (insulin detemir)** is appropriately dosed and does not require adjustment. *Reduce insulin detemir doses by 10-20% and continue current prandial insulin* - Reducing **insulin detemir**, a basal insulin, would likely lead to **hyperglycaemia** in the fasting state and before meals, where the patient's levels are currently well-controlled. - This adjustment would not address the **post-prandial hypoglycaemia**, which is linked to the mealtime rapid-acting insulin. *Switch from insulin detemir twice daily to insulin glargine once daily at same total dose* - There is no clinical reason to switch the type or frequency of **basal insulin** as the current regimen of insulin detemir is effectively maintaining target pre-meal and fasting glucose levels. - This change would not resolve the problem of **post-prandial hypoglycaemia** caused by an excessive dose of mealtime insulin aspart. *Increase carbohydrate intake at each meal and continue current insulin regimen* - Increasing **carbohydrate intake** to match an excessive insulin dose is generally not recommended, especially in pregnancy, as it can lead to **unnecessary weight gain** and complicate overall glycaemic management. - The preferred approach is to adjust the **insulin dose** to fit the patient's usual dietary intake, rather than altering diet to compensate for an incorrect insulin dose. *Reduce insulin aspart by 2 units and add mid-meal snacks with 1-2 units insulin aspart* - While reducing insulin aspart is appropriate, adding additional **rapid-acting insulin** for mid-meal snacks can increase the complexity of the regimen and the risk of **insulin stacking**, potentially worsening hypoglycaemia. - The primary goal is to correct the initial over-dosing of mealtime insulin that is causing the post-prandial lows, rather than introducing more insulin doses.

Question 30: A 64-year-old man with permanent atrial fibrillation is established on edoxaban 60mg once daily. He requires urgent colonoscopy in 48 hours for suspected lower gastrointestinal bleeding that has now settled. His haemoglobin is 98 g/L (down from baseline 135 g/L). His renal function shows eGFR 52 ml/min/1.73m² and weight is 74kg. What is the most appropriate management of his anticoagulation for the procedure?

A. Continue edoxaban without interruption as colonoscopy is low bleeding risk
B. Omit edoxaban on the morning of the procedure and restart 24 hours post-procedure
C. Stop edoxaban 48 hours before procedure and restart 48-72 hours post-procedure
D. Stop edoxaban 24 hours before procedure and restart 6 hours post-procedure if haemostasis secure (Correct Answer)
E. Switch to unfractionated heparin infusion 24 hours before procedure

Explanation: ***Stop edoxaban 24 hours before procedure and restart 6 hours post-procedure if haemostasis secure*** - For high bleeding risk procedures like a **colonoscopy** (especially during suspected GI bleed), **edoxaban** should be withheld for at least **24 hours** (roughly 2 half-lives) in patients with **CrCl >30 ml/min**. - Post-procedure, restarting within **6 to 8 hours** is appropriate once **haemostasis** is confirmed, balancing the reduction of **thromboembolic risk** against the risk of post-polypectomy bleeding. *Continue edoxaban without interruption as colonoscopy is low bleeding risk* - A colonoscopy is classified as a **high bleeding risk** procedure, particularly when biopsies or **polypectomy** might be performed during the investigation of a GI bleed. - Continuing anticoagulation would significantly increase the hazardous risk of **intra-procedural bleeding**. *Omit edoxaban on the morning of the procedure and restart 24 hours post-procedure* - Omitting only on the morning of the procedure is insufficient, as significant **anticoagulant effect** remains from the previous day's dose. - Delaying the restart until 24 hours post-procedure unnecessarily extends the window of **stroke risk** in a patient with **atrial fibrillation**. *Stop edoxaban 48 hours before procedure and restart 48-72 hours post-procedure* - A 48-hour pre-procedural cessation is only recommended for **Factor Xa inhibitors** when the **eGFR is <30 ml/min**, which is not the case here (eGFR 52). - Restarting after **48-72 hours** is considered an excessive delay that increases the likelihood of a **thromboembolic event**. *Switch to unfractionated heparin infusion 24 hours before procedure* - Heparin **bridging** is generally not recommended for **Direct Oral Anticoagulants (DOACs)** due to their predictable pharmacokinetics and rapid onset/offset. - Using heparin in this context increases the overall **bleeding risk** without providing superior protection against **ischaemic stroke** compared to simple DOAC omission.

Practice by Chapter

Anticoagulant safety

Practice Questions

High-risk medicines

Practice Questions

Insulin safety

Practice Questions

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free